NASDAQ:TYRA Tyra Biosciences Q1 2023 Earnings Report $9.91 +0.30 (+3.12%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Tyra Biosciences EPS ResultsActual EPS-$0.28Consensus EPS -$0.37Beat/MissBeat by +$0.09One Year Ago EPSN/ATyra Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ATyra Biosciences Announcement DetailsQuarterQ1 2023Date5/4/2023TimeN/AConference Call DateThursday, May 4, 2023Conference Call Time7:00AM ETUpcoming EarningsTyra Biosciences' Q2 2025 earnings is scheduled for Wednesday, August 6, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Tyra Biosciences Earnings HeadlinesTyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025July 8 at 4:17 PM | prnewswire.comTyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) - FinanzNachrichten.deJuly 2, 2025 | finanznachrichten.deA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. July 8 at 2:00 AM | Porter & Company (Ad)Tyra Biosciences Doses First Patient in Phase 2 Study of TYRA-300 in Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302)June 30, 2025 | prnewswire.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12, 2025 | prnewswire.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.comSee More Tyra Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Tyra Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tyra Biosciences and other key companies, straight to your email. Email Address About Tyra BiosciencesTyra Biosciences (NASDAQ:TYRA) is a clinical-stage biotechnology company headquartered in South San Francisco, California, that focuses on the discovery and development of precision oncology therapies. Founded in 2019, the company leverages a structure-based drug design platform to identify and optimize small-molecule inhibitors that target cancer-driving proteins. Tyra Biosciences has built a pipeline of novel compounds designed to address genetically defined patient populations with high unmet medical need. The company’s core activities span target discovery, medicinal chemistry, and preclinical development. Utilizing computational modeling and biophysical screening techniques, Tyra Biosciences aims to create molecules with high selectivity and favorable pharmacokinetic properties. Its preclinical portfolio includes candidates designed to inhibit mutant kinases and modulate protein homeostasis pathways, with the goal of advancing lead compounds into Investigational New Drug (IND) applications. Tyra Biosciences serves a global oncology community through strategic collaborations with academic research institutions and contract research organizations. The company’s research programs benefit from partnerships that provide access to translational biology expertise, patient-derived models, and biomarkers to guide clinical strategy. Although primarily based in the United States, Tyra Biosciences maintains engagement with international investigators to support multi-regional studies. Under the leadership of Chief Executive Officer Dr. Elan Holman and a management team with extensive experience in cancer drug development, Tyra Biosciences is committed to advancing targeted therapies from the laboratory to the clinic. The company’s scientific advisory board comprises seasoned oncology researchers who contribute to program prioritization and clinical design, positioning Tyra Biosciences to address critical gaps in precision medicine.Written by Jeffrey Neal JohnsonView Tyra Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Smith & Wesson Stock Falls on Earnings Miss, Tariff WoesWhat to Expect From the Q2 Earnings Reporting CycleBroadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record Highs Upcoming Earnings Bank of America (7/14/2025)America Movil (7/15/2025)Bank of New York Mellon (7/15/2025)BlackRock (7/15/2025)Citigroup (7/15/2025)JPMorgan Chase & Co. (7/15/2025)Progressive (7/15/2025)Charles Schwab (7/15/2025)UnitedHealth Group (7/15/2025)Wells Fargo & Company (7/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
